Scandion Oncology announces that its President & CEO has bought 4,500 shares in Scandion Oncology

Scandion Oncology A/S (“Scandion Oncology”) announces that its President & CEO, Bo Rode Hansen, has bought additional 4,500 shares in Scandion Oncology resulting in a total holding on 40,400 shares in the Company.

For further information regarding Scandion Oncology A/S, please contact:


Bo Rode Hansen, President & CEO

Phone: +45 3810 2017



The information was provided by the contact person above for publication on July 19, 2021.

About Scandion Oncology A/S
Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs, offering the potential for better response rates, longer survival and improved quality of life. The first-in-class lead candidate, SCO-101, is currently in clinical Phase II. The Company is targeting cancer drug resistance in various treatment modalities including chemotherapy, anti-hormonal therapy and immunotherapy. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.

For more information, please visit and sign up for news releases.
For frequent updates, please also follow us on LinkedIn and Twitter.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at or +46 (0) 40 200 250.